Welcome to our dedicated page for Denali Cap Acqsn SEC filings (Ticker: DECAU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode a SPAC’s paperwork can feel like searching for a target in the dark. Denali Capital Acquisition Corp’s filings pack trust-account math, redemption terms, warrant adjustments, and sponsor incentives into dense legal prose. Whether you need “Denali Capital Acquisition Corp insider trading Form 4 transactions” before a vote or want the fine print behind a postponed extraordinary general meeting, the details matter—and they’re rarely obvious.
Stock Titan’s AI resolves that problem. Our engine reads every 10-K, 10-Q, S-4, and 8-K the moment it hits EDGAR, then surfaces what busy analysts look for:
- Real-time alerts for “Denali Capital Acquisition Corp Form 4 insider transactions real-time,” pinpointing sponsor or executive stock moves
- Clear highlights of 8-K material events—search “Denali Capital Acquisition Corp 8-K material events explained” and skip straight to the outcome
- Sentence-level summaries that make “Denali Capital Acquisition Corp SEC filings explained simply” more than a promise
- AI commentary tying trust-account shifts to potential dilution so you can perform an immediate “Denali Capital Acquisition Corp earnings report filing analysis” even though SPACs report minimal revenue
Looking for deeper context? Our dashboards connect specific forms to the questions investors actually ask:
- 10-Q pages flagged for cash burn so your “Denali Capital Acquisition Corp quarterly earnings report 10-Q filing” review takes minutes
- 10-K excerpts that turn “Denali Capital Acquisition Corp annual report 10-K simplified” into actionable insight
- Proxy extracts covering dilution caps and board pay for anyone googling “Denali Capital Acquisition Corp proxy statement executive compensation”
- One-click guidance on “understanding Denali Capital Acquisition Corp SEC documents with AI” for newcomers to SPAC structures
From trust-account withdrawals to “Denali Capital Acquisition Corp executive stock transactions Form 4,” every disclosure is indexed, summarized, and updated in real time—so you focus on the potential deal, not the paperwork.
Denali Capital Acquisition Corp. completed an $82.5 million initial public offering of 8,250,000 public units and a concurrent private placement of 510,000 units for $5.1 million, depositing approximately $84.15 million into a trust account that was invested in short-term U.S. government securities or money market funds. Significant redemptions reduced public shares outstanding, with approximately $40.5 million removed (3,712,171 shares) and later approximately $43.4 million removed (3,785,992 shares), leaving 751,837 public shares outstanding at one point and later 43,739 public shares outstanding as of June 30, 2025.
The company repeatedly extended its deadline to consummate an initial business combination by funding the trust with sponsor and third-party convertible promissory note draws and extensions, and recorded working capital loans and convertible notes from the Sponsor, FutureTech, Scilex and others with aggregate outstanding balances disclosed (for example, $1,574,970 outstanding under sponsor loans and $1,275,000 outstanding to FutureTech as of June 30, 2025). The filing discloses a proposed business combination with Semnur Pharmaceuticals with Semnur equity value stated at $2,500,000,000, and notes the company was delisted from Nasdaq on April 16, 2025 and began OTC trading on April 17, 2025.
Meteora Capital, LLC and its managing member Vik Mittal filed a Schedule 13G/A stating they do not beneficially own any shares of Denali Capital Acquisition Corp.'s Class A common stock (CUSIP G6256B106). The filing identifies Meteora as an investment adviser organized in Delaware that manages certain funds and accounts (the Meteora Funds) but reports zero shares, zero voting power, and 0% of the class. The document certifies the securities are held (or not held) in the ordinary course of business and not to influence control of the issuer.
Denali Capital Acquisition Corp. submitted a Form NT 10-Q notifying the SEC it did not file its quarterly report for the period ended June 30, 2025 on time. The company checked the box stating it will file the subject report within the 15-calendar-day extension permitted under Rule 12b-25. The form indicates all other required periodic reports for the prior 12 months have been filed, and the company does not anticipate a significant change in results of operations compared with the prior period. The notice is dated August 14, 2025 and is signed by Lei Huang, Chief Executive Officer. The registrant's principal executive office address is listed as 437 Madison Avenue, 27th Floor, New York, NY 10022.
Denali Capital Acquisition Corp. proposes to domesticize from the Cayman Islands to Delaware and complete a business combination with Semnur Pharmaceuticals ("Semnur"). Under the Merger Agreement, Semnur will become a wholly owned subsidiary of Denali and Denali will be renamed Semnur Pharmaceuticals, Inc. The merger consideration is stated as an aggregate $2.5 billion in newly issued shares of the combined company, determined by CB Capital's valuation opinion. Following closing, Scilex (Semnur's parent) will directly hold approximately 83.8% of common stock and 2.5% of Series A preferred stock, representing 86.3% of voting power. The filing registers 292,476,239 common shares, 524,622 units, 6,000,000 Series A preferred shares and 8,760,000 warrants. A shareholder meeting is set for September 3, 2025. Denali was delisted from Nasdaq and currently trades on the OTC Markets; a Nasdaq listing application for New Semnur is pending but not assured. The proxy discloses sponsor interests, related party transactions and estimated transaction reimbursements of approximately $10.5 million.
This joint Schedule 13G/A is filed on behalf of TD Securities (USA) LLC, Cowen Financial Products LLC, Toronto Dominion Holdings (U.S.A.), Inc., TD Group US Holdings LLC and The Toronto-Dominion Bank reporting their position in Denali Capital Acquisition Corp.
The filers state they beneficially own 0 Class A ordinary shares (CUSIP G6256B106), representing 0% of the class, and attach a joint filing agreement and a certification that the securities were not acquired to influence control.
Denali Capital Acquisition Corp. reported that it deposited $874.78 into its Trust Account to extend the period to consummate a business combination by one month, moving the deadline from August 11, 2025 to September 11, 2025. The disclosure appears under Item 8.01 (Other Events) and the filing also references an Inline XBRL cover page exhibit.
The filing lists the registrant's registered securities (Units: DNQUF; Class A shares: DNQAF; Warrants: DNQWF) and is signed by Chief Executive Officer Lei Huang. The deposit is presented as the action taken to extend the SPAC's contractual combination deadline by one month.
Amendment No. 6 to the Form S-4 is an exhibits-only filing that updates Exhibit 107 and does not change the proxy statement/prospectus substantive disclosures. The filing confirms that Denali Capital Acquisition Corp. intends to effect a domestication from the Cayman Islands to Delaware and, in connection with the Business Combination, change its corporate name to Semnur Pharmaceuticals, Inc. The Registration Statement treats the continuing entity as the Company following the Domestication and Business Combination.
Item 21 lists exhibits and schedules including the Agreement and Plan of Merger and its amendments, forms of certificates of domestication and incorporation, registration and stockholder agreements, multiple convertible promissory notes, a 2024 Semnur stock option plan, a fairness opinion by CB Capital Partners, and consents from counsel and auditors. Certain exhibits are omitted or redacted under Regulation S-K and Item 601(b)(10), with the registrant agreeing to furnish omitted materials to the SEC upon request.
Denali Capital Acquisition Corp. proposes a business combination with Semnur Pharmaceuticals that would domesticize Denali to Delaware and rename it Semnur Pharmaceuticals, Inc. The merger consideration is equity with an aggregate value of $2.5 billion as of the Merger Agreement date, supported by a fairness opinion from CB Capital. The filing registers 292,476,239 New Semnur common shares, 524,622 units, 6,000,000 Series A preferred shares and 8,760,000 warrants to be issued in the transaction.
The transaction would leave Scilex as the controlling stockholder: approximately 83.8% of common stock and 2.5% (6,000,000) preferred, giving it about 86.3% voting power. Denali public shareholders would retain under 0.1% ownership in a no-redemption scenario, and significant dilution is possible from outstanding and potential warrants and options (including a referenced 50,000,000 potential options). Denali was delisted from Nasdaq on April 16, 2025 and currently trades on the OTC Markets; a Nasdaq listing application for New Semnur is pending but not assured. Related-party arrangements and reimbursements to Sponsor total an estimated $10.5 million of transaction and loan obligations.
FAQ
What is the current stock price of Denali Cap Acqsn (DECAU)?
